Transcriptional Regulation in Cancers and Metabolic Diseases
The transcription factor (TF) mediated regulation of gene expression is a process fundamental to all biological and physiological processes. Genetic changes and epigenetic modifications of TFs affect target gene expression during the formation of malignant cells. Extensive work has been done on the...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2015 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (98 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547426704498 |
---|---|
ctrlnum |
(CKB)3710000000631146 (oapen)https://directory.doabooks.org/handle/20.500.12854/61176 (EXLCZ)993710000000631146 |
collection |
bib_alma |
record_format |
marc |
spelling |
Carol Prives auth Transcriptional Regulation in Cancers and Metabolic Diseases Frontiers Media SA 2015 1 electronic resource (98 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics The transcription factor (TF) mediated regulation of gene expression is a process fundamental to all biological and physiological processes. Genetic changes and epigenetic modifications of TFs affect target gene expression during the formation of malignant cells. Extensive work has been done on the critical TFs in various disease models. Despite the success of numerous TF-targeted therapies, there remain significant hurdles understanding the mechanisms, transcriptional targets and networks of physiologic pathways that govern TF action. This effort is now beginning to produce exciting new avenues of research. A clinically relevant topic for genetic change of TF is the mutant isoforms of p53, the most famous tumor suppressor. The p53 mutations either results in loss of function, or acting as dominant negative for wild-type protein, or ‘gain of function’ specifically promoting cancer survival. The gain of function is achieved by shifting p53 binding partner proteins, or changed genomic binding landscape leading to a cancer-promoting transcriptome. Another example of genetic change of TF causing malignancy is the AML-ETO fusion protein in the human t(8;21)-leukemia. The fusion protein is an active TF, and more interestingly, new studies link the disease causing role of AML-ETO to the unique transcriptome in the hematopoietic stem cells. Nuclear receptors (NR) are a group of ligand-dependent TFs governing the expression of genes involved in a broad range of reproductive, developmental and metabolic programs. Genetic changes and epigenetic modifications of NRs lead to cancers and metabolic diseases. Androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) are well studied NRs in prostate, breast and endometrial cancers. The development in sequencing technology and computational genomics enable us to investigate the transcription programs of these master TFs in an unprecedented level. This Research Topic aims to present the most up-to-date progress in the field of transcription regulation in cancers and metabolic diseases. English senescence Cell Cycle Cancer stem cell nuclear receptor microRNA p63 exosome tran epigenetics p53 2-88919-712-3 Wen Zhou auth |
language |
English |
format |
eBook |
author |
Carol Prives |
spellingShingle |
Carol Prives Transcriptional Regulation in Cancers and Metabolic Diseases Frontiers Research Topics |
author_facet |
Carol Prives Wen Zhou |
author_variant |
c p cp |
author2 |
Wen Zhou |
author2_variant |
w z wz |
author_sort |
Carol Prives |
title |
Transcriptional Regulation in Cancers and Metabolic Diseases |
title_full |
Transcriptional Regulation in Cancers and Metabolic Diseases |
title_fullStr |
Transcriptional Regulation in Cancers and Metabolic Diseases |
title_full_unstemmed |
Transcriptional Regulation in Cancers and Metabolic Diseases |
title_auth |
Transcriptional Regulation in Cancers and Metabolic Diseases |
title_new |
Transcriptional Regulation in Cancers and Metabolic Diseases |
title_sort |
transcriptional regulation in cancers and metabolic diseases |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2015 |
physical |
1 electronic resource (98 p.) |
isbn |
2-88919-712-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT carolprives transcriptionalregulationincancersandmetabolicdiseases AT wenzhou transcriptionalregulationincancersandmetabolicdiseases |
status_str |
n |
ids_txt_mv |
(CKB)3710000000631146 (oapen)https://directory.doabooks.org/handle/20.500.12854/61176 (EXLCZ)993710000000631146 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Transcriptional Regulation in Cancers and Metabolic Diseases |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796651476903264256 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03167nam-a2200397z--4500</leader><controlfield tag="001">993547426704498</controlfield><controlfield tag="005">20231214133653.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2015 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000631146</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/61176</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000631146</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carol Prives</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Transcriptional Regulation in Cancers and Metabolic Diseases</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (98 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The transcription factor (TF) mediated regulation of gene expression is a process fundamental to all biological and physiological processes. Genetic changes and epigenetic modifications of TFs affect target gene expression during the formation of malignant cells. Extensive work has been done on the critical TFs in various disease models. Despite the success of numerous TF-targeted therapies, there remain significant hurdles understanding the mechanisms, transcriptional targets and networks of physiologic pathways that govern TF action. This effort is now beginning to produce exciting new avenues of research. A clinically relevant topic for genetic change of TF is the mutant isoforms of p53, the most famous tumor suppressor. The p53 mutations either results in loss of function, or acting as dominant negative for wild-type protein, or ‘gain of function’ specifically promoting cancer survival. The gain of function is achieved by shifting p53 binding partner proteins, or changed genomic binding landscape leading to a cancer-promoting transcriptome. Another example of genetic change of TF causing malignancy is the AML-ETO fusion protein in the human t(8;21)-leukemia. The fusion protein is an active TF, and more interestingly, new studies link the disease causing role of AML-ETO to the unique transcriptome in the hematopoietic stem cells. Nuclear receptors (NR) are a group of ligand-dependent TFs governing the expression of genes involved in a broad range of reproductive, developmental and metabolic programs. Genetic changes and epigenetic modifications of NRs lead to cancers and metabolic diseases. Androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) are well studied NRs in prostate, breast and endometrial cancers. The development in sequencing technology and computational genomics enable us to investigate the transcription programs of these master TFs in an unprecedented level. This Research Topic aims to present the most up-to-date progress in the field of transcription regulation in cancers and metabolic diseases.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">senescence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cell Cycle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer stem cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nuclear receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">p63</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exosome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tran</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">p53</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-712-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wen Zhou</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 06:02:06 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-04-12 04:07:06 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338570530004498&Force_direct=true</subfield><subfield code="Z">5338570530004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338570530004498</subfield></datafield></record></collection> |